Search results for " protocols"

showing 10 items of 761 documents

Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is…

2006

BACKGROUND AND OBJECTIVES: This European Group for Blood and Marrow Transplantation (EBMT) multicentre randomized phase III study was designed to assess the safety and efficacy of CD34+ selection in newly diagnosed myeloma patients undergoing autologous transplantation. DESIGN AND METHODS: One hundred and eleven patients responsive to initial chemotherapy were randomized to receive CD34+ selected (arm A) or unselected PBPC (arm B) after conditioning with high-dose melphalan and TBI. ASO-PCR was used to assess purging efficacy and reinfused tumor load. Tumor load could be assessed in 59 patients. RESULTS: CD34+ selection gave a median tumor cell depletion of 2.2 logs (0.77-5.96). No tumor ce…

autologous transplantMelphalanOncologyAdultMaleRiskmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentAntigens CD34Transplantation AutologousDexamethasoneDisease-Free SurvivalPostoperative ComplicationsRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineEuropean Group for Blood and Marrow TransplantatioAutologous transplantationHumansSurvival rateSurvival analysisMultiple myelomaAgedChemotherapyPeripheral Blood Stem Cell TransplantationHematologybusiness.industryBone Marrow PurgingHematologyCD34+ selectionMiddle Agedmedicine.diseasePrognosisSurvival AnalysisBone marrow purgingSurgerySurvival RateTreatment OutcomeDoxorubicinVincristineFemalebusinessMultiple Myelomamedicine.drugFollow-Up StudiesHaematologica
researchProduct

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.

2020

INTRODUCTION: Pancreatic cancer (PC), even in the absence of metastatic disease, has a dismal prognosis. One-third of them are borderline resectable (BRPC) or locally advanced unresectable PC (LAUPC) at diagnosis. There are limited prospective data supporting the best approach on these tumours. Neoadjuvant chemotherapy (ChT) is being increasingly used in this setting. METHODS: This is a retrospective series of consecutive patients staged as BRPC or LAUPC after discussion in the multidisciplinary board (MDB) at an academic centre. All received neoadjuvant ChT, followed by chemoradiation (ChRT) in some cases, and those achieving enough downstaging had a curative-intent surgery. Descriptive da…

borderline resectableCancer Researchmedicine.medical_specialtyFOLFIRINOXmedicine.medical_treatmentpancreatic cancerNeutropeniaAdenocarcinomalcsh:RC254-282Pancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective Studies1506Neoadjuvant therapyRetrospective StudiesOriginal ResearchChemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslocally advanced unresectableNeoadjuvant TherapyOxaliplatinSurgeryIrinotecanPancreatic NeoplasmsFOLFIRINOXOncologyFluorouracilbusinessmedicine.drugESMO open
researchProduct

Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-sp…

2012

Cetuximab is a human/mouse chimeric IgG1 monoclonal antibody (mAb) to epidermal growth factor receptor, approved for colorectal carcinoma treatment in combination with chemotherapy. The immune-mediated effects elicited by its human fraction of crystallization moiety might critically contribute to the overall anti-tumor effectiveness of the antibody. We therefore investigated cetuximab ability to promote colon cancer cell opsonization and phagocytosis by human dendritic cells (DCs) that are subsequently engaged in antigen-cross presentation to cytotoxic T-lymphocyte (CTL) precursors. Human colon cancer cell lines were evaluated for susceptibility to DC-mediated phagocytosis before and after …

cetuximab; chemotherapy; danger signal; cytotoxic-T-lymphocytes; phagocytosisCancer ResearchColorectal cancerSettore MED/06 - Oncologia MedicaAntigen-Presenting CellsAntibodies Monoclonal Humanizedchemotherapydanger signalCross-PrimingAntigenAntigens NeoplasmCell Line TumorAntineoplastic Combined Chemotherapy ProtocolscetuximabHumansMedicineCytotoxic T cellCetuximabbusiness.industrySettore BIO/14Antibodies MonoclonalphagocytosisDendritic CellsDendritic cellmedicine.diseasecytotoxic-T-lymphocytedigestive system diseasesTumor antigenCTL*OncologyColonic NeoplasmsCancer cellImmunologyLeukocytes MononuclearCancer researchbusinessHT29 Cellscytotoxic-T-lymphocytesT-Lymphocytes Cytotoxicmedicine.drug
researchProduct

LPV model identification for gain scheduling control: An application to rotating stall and surge control problem

2006

Abstract We approach the problem of identifying a nonlinear plant by parameterizing its dynamics as a linear parameter varying (LPV) model. The system under consideration is the Moore–Greitzer model which captures surge and stall phenomena in compressors. The control task is formulated as a problem of output regulation at various set points (stable and unstable) of the system under inputs and states constraints. We assume that inputs, outputs and scheduling parameters are measurable. It is worth pointing out that the adopted technique allows for identification of an LPV model's coefficients without the requirements of slow variations amongst set points. An example of combined identification…

decentralized controlEngineeringbusiness.industryApplied MathematicsSystem identificationStall (fluid mechanics)Control engineeringconsensus protocolOptimal controlconsensus protocolsDecentralised systemComputer Science Applicationsoptimal controlNonlinear systemGain schedulingControl and Systems EngineeringControl theorynetworksSettore MAT/09 - Ricerca OperativaElectrical and Electronic EngineeringSurgebusinessSurge controlconsensus protocols; decentralized control; optimal control; networksControl Engineering Practice
researchProduct

Decentralized classification in societies of autonomous and heterogenous robots

2011

This paper addresses the classification problem for a set of autonomous robots that interact with each other. The objective is to classify agents that “behave” in “different way”, due to their own physical dynamics or to the interaction protocol they are obeying to, as belonging to different “species”. This paper describes a technique that allows a decentralized classification system to be built in a systematic way, once the hybrid models describing the behavior of the different species are given. This technique is based on a decentralized identification mechanism, by which every agent classifies its neighbors using only local information. By endowing every agent with such a local classifie…

distributed algorithm0106 biological sciencesSpecies classification0209 industrial biotechnologyEngineeringbusiness.industrymulti-robot systemInteraction protocolRoboticsMobile robot02 engineering and technologyAutonomous robotconsensus protocols010603 evolutionary biology01 natural sciencesComputer Science::Multiagent SystemsIdentification (information)020901 industrial engineering & automationSettore ING-INF/04 - AutomaticaRobotArtificial intelligenceSet (psychology)businessClassifier (UML)2011 IEEE International Conference on Robotics and Automation
researchProduct

Orthognathic surgery and aligners. A comparative assessment of periodontal health and quality of life in postsurgical orthodontic treatment with alig…

2023

Removable clear aligners have become very popular in the last few decades, but they are still little used in the field of orthognathic surgery (OS). The objective of this study was to compare periodontal health and quality of life (QoL) associated to postsurgical orthodontic treatment. Patients with dentofacial deformities undergoing OS were randomly allocated to receive postsurgical orthodontic treatment with either fixed orthodontic appliances or Invisalign. The main outcomes were periodontal health and QoL. Plaque index, probing depth and bleeding on probing were assessed as periodontal health indicators. QoL was assessed through the Orthognathic Quality of Life Questionnaire (OQLQ-22) a…

general surgerysurgical oncology postoperative complicationsperioperative careOtorhinolaryngologyclinical protocolsdental careSurgeryGeneral DentistryUNESCO:CIENCIAS MÉDICASMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized …

2008

Summary Purpose A phase III randomized trial was carried out to compare two schedules of the vinorelbine (VNR)–cisplatin (CDDP) regimen in patients with locally advanced unresectable poor prognosis stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoints were overall survival (OS) and analysis of toxicity, while secondary endpoints included response rates, time-to-progression (TTP) and quality of life (QoL). Patients and methods Eligible patients were randomized to receive: (a) VNR 25 mg/m 2 on day 1, 8 and 15 plus CDDP 100 mg/m 2 on day 1 every 4 weeks or (b) VNR 30 mg/m 2 on day 1 and 8 plus CDDP 80 mg/m 2 on day 1 every 3 weeks. All patients were chemotherapy-n…

inorganic chemicalsPulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyRandomizationLung NeoplasmsVinorelbineVinblastineGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerProspective cohort studyneoplasmsAgedNeoplasm StagingChi-Square Distributionbusiness.industryVinorelbineMiddle Agedmedicine.diseaseVinblastineSurgeryRegimenLogistic ModelsTreatment OutcomeOncologyItalyDisease ProgressionQuality of LifeFemaleCisplatinbusinessFebrile neutropeniamedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells.

2000

This paper studies the effects caused in human retinoblastoma Y79 cells by treatment with combinations of sodium butyrate, the inhibitor of topoisomerase I camptothecin and the inhibitor of 26S proteasome MG132. The combination of sodium butyrate and camptothecin resulted in a strong synergistic cytotoxicity, as revealed by combination indices of 0.77 and 0.52 calculated at IC(50) and IC(75). Synergistic interactions were also demonstrated for combinations of sodium butyrate and MG132, camptothecin and MG132 and for a combination of all three compounds. The cytotoxic effects observed after the combined treatments can be considered a consequence of apoptosis, as suggested by the appearance o…

medicine.drug_classCell SurvivalLeupeptinsSodiumchemistry.chemical_elementApoptosisButyrateBiologyCysteine Proteinase Inhibitorschemistry.chemical_compoundMG132Antineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedHumansheterocyclic compoundsEnzyme InhibitorsRetinoblastomaCaspase 3TopoisomeraseRetinoblastomaSodium butyrateDrug SynergismGeneral Medicinemedicine.diseaseeye diseasesEnzyme ActivationButyrateschemistryBiochemistryProto-Oncogene Proteins c-bcl-2CaspasesCancer researchbiology.proteinCamptothecinTopoisomerase I InhibitorsTumor Suppressor Protein p53CamptothecinTopoisomerase inhibitormedicine.drugTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
researchProduct

Anti-endothelin drugs in solid tumors

2010

Importance of the field: The endothelin (ET) axis, which includes the biological functions of ETs and their receptors, has played a physiological role in normal tissue, acting as a modulator of vasomotor tone, tissue differentiation and development, cell proliferation and hormone production. Interestingly, it also functions in the growth and progression of various tumors. Several researchers have identified the blockade of the ET-1 receptor as a promising therapeutic approach. Areas covered in this review: The clinical investigation of an orally bioavailable ET antagonist, atrasentan, in prostate cancer, is encouraging. In this neoplasia, it has shown antitumor activity, bone metastasis con…

medicine.hormoneEndothelin Receptor AntagonistsMalemedicine.medical_specialtyPyrrolidinesSettore MED/06 - Oncologia Medicaatrasentan endothelins prostate cancer zibotentanModels BiologicalEndothelinsProstate cancerchemistry.chemical_compoundDrug Delivery SystemsInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)ReceptorPharmacologyZibotentanbusiness.industryReceptors EndothelinEndothelinsAtrasentanBone metastasisProstatic NeoplasmsDrugs Investigationalmedicine.diseaseBlockadeEndocrinologychemistryAtrasentanCancer researchEndothelin receptorbusinessmedicine.drugSignal Transduction
researchProduct

Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma?

2020

Abstract Aim This paper aims to analyze the usefulness of the G8 geriatric oncology questionnaire in patients with advanced/metastatic pancreatic adenocarcinoma (aPAC) and its possible association with different clinical outcomes. Methods Patients age > 70 years were screened with the G8 tool and treated with intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 for 3 consecutive weeks followed by one-week rest as prescribed after clinical evaluation by treating oncologists. Patient’s charts were evaluated for type and severity of toxicity, 2 cycle rate of completion, discontinuation rate, delays, dose reductions, and other outcomes response rates, progression-free, and overall su…

medicine.medical_specialtyAdenocarcinoma03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineGeriatric AssessmentAgedResponse rate (survey)business.industryGeriatric assessmentGemcitabine Maintenance Nab-paclitaxel Older adults Pancreatic cancerMetastatic Pancreatic Adenocarcinomamedicine.diseaseGemcitabineDiscontinuationPancreatic NeoplasmsOncologyGeriatric oncology030220 oncology & carcinogenesisToxicityGeriatrics and Gerontologybusinessmedicine.drug
researchProduct